To our knowledge, this work is the first to describe the generation of FLT3-ITD mutants using human myeloid leukemia cells and the CRISPR-Cas9 system; these cells lines allowed us to elucidate the relationship between the FLT3-ITD mutation and CD52 overexpression. The gene discussed is CD52; the disease is myeloid leukemia.